Stock is up.... Sales going up. Looks like the word is getting out that the loser RSS's are either, quitting or getting fired, making way for sales professionals that can actually sell! Either way... good for OPKO and share holders!
Stock is UP!!
- Thread starter anonymous
- Start date
-
- Tags
- None
Do not listen to the noise. we know whats going on.
Great advice, HGH make or break, if a failure then stock tanks if positive news then stock rocks, anyones guess, pray for positive news as little around here is positive.
Any other company with inept management similar to what we have at Opko would be fired for their catastrophic results, Opko down stock price down 60% YOY. Those who are responsible for this epic failure should be fired ASAP and a class action law suit filed against the Opko board of directors for not acting sooner.
It will climb back up and all this chatter on here is nonsense.
You provide a forward speaking statement without any backup, as if your some kind of Houdini, hate to break it to you pal but investors don' t make decisions based on CP. Agree with previous poster, investors listened to the plan and bought in big time to fund what turned out to be disaster when the rest of the stock market soared. We stock holders demand answers! Fire management!
Nice job Opko management, your continued failure is on display with your stock price today, just hit the 52 week low point. How low will it go with your management team still in place is anyones guess, look out below here comes the falling Opko knife, shame.
Management at Opko, please resign already! When are you going to realize you have fucked up royally! Thanks to your guidance you have brought the price of Opko stock near it's 5 year low, quite an accomplishment in such a short period of time, unreal. Know this, exAmgen managers have a reputation for failure outside of Amgen and Opko proves it again.
Stock dow in protrude $.08, don't attempt to catch a falling knife and charts look like there isn't going to be a dead cat bounce any time soon unless Dr Phil shifts gears and fires those managers responsible for this mess.
Opko Health, Inc. (OPK) Position Boosted by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP boosted its stake in Opko Health, Inc. (NASDAQ:OPK) by 8.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,762,540 shares of the biotechnology company’s stock after buying an additional 141,412 shares during the period. Dimensional Fund Advisors LP owned 0.32% of Opko Health worth $11,598,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Opko Health by 11,481.3% during the 1st quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock valued at $181,163,000 after purchasing an additional 22,449,752 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Opko Health by 3,687.6% during the 2nd quarter. Alps Advisors Inc. now owns 504,924 shares of the biotechnology company’s stock valued at $3,322,000 after purchasing an additional 491,593 shares in the last quarter. Credit Suisse AG boosted its position in shares of Opko Health by 122.0% during the 1st quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after purchasing an additional 410,445 shares in the last quarter. Jaffetilchin Investment Partners LLC boosted its position in shares of Opko Health by 54.0% during the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 1,006,464 shares of the biotechnology company’s stock valued at $6,623,000 after purchasing an additional 353,104 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Opko Health by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock valued at $175,151,000 after purchasing an additional 296,757 shares in the last quarter. Hedge funds and other institutional investors own 22.66% of the company’s stock.
Opko Health, Inc. (NASDAQ OPK) opened at $4.73 on Thursday. Opko Health, Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $12.15. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01.
Opko Health (NASDAQ:OPK) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm had revenue of $263.50 million during the quarter, compared to analyst estimates of $319.43 million. During the same quarter in the previous year, the business earned ($0.03) earnings per share. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. sell-side analysts expect that Opko Health, Inc. will post -0.27 EPS for the current fiscal year.
In other Opko Health news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the transaction, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Phillip Md Et Al Frost acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average cost of $6.10 per share, for a total transaction of $152,500.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $18,720,601.10. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 1,126,038 shares of company stock valued at $4,828,540. Corporate insiders own 40.19% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Thursday, October 12th. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $16.00 price objective on shares of Opko Health in a research report on Monday, September 25th. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 23rd. Finally, J P Morgan Chase & Co cut shares of Opko Health from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $12.00 to $7.00 in a report on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $13.97.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Opko Health by 11,481.3% during the 1st quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock valued at $181,163,000 after purchasing an additional 22,449,752 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Opko Health by 3,687.6% during the 2nd quarter. Alps Advisors Inc. now owns 504,924 shares of the biotechnology company’s stock valued at $3,322,000 after purchasing an additional 491,593 shares in the last quarter. Credit Suisse AG boosted its position in shares of Opko Health by 122.0% during the 1st quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after purchasing an additional 410,445 shares in the last quarter. Jaffetilchin Investment Partners LLC boosted its position in shares of Opko Health by 54.0% during the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 1,006,464 shares of the biotechnology company’s stock valued at $6,623,000 after purchasing an additional 353,104 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Opko Health by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock valued at $175,151,000 after purchasing an additional 296,757 shares in the last quarter. Hedge funds and other institutional investors own 22.66% of the company’s stock.
Opko Health, Inc. (NASDAQ OPK) opened at $4.73 on Thursday. Opko Health, Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $12.15. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01.
Opko Health (NASDAQ:OPK) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm had revenue of $263.50 million during the quarter, compared to analyst estimates of $319.43 million. During the same quarter in the previous year, the business earned ($0.03) earnings per share. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. sell-side analysts expect that Opko Health, Inc. will post -0.27 EPS for the current fiscal year.
In other Opko Health news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the transaction, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Phillip Md Et Al Frost acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average cost of $6.10 per share, for a total transaction of $152,500.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $18,720,601.10. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 1,126,038 shares of company stock valued at $4,828,540. Corporate insiders own 40.19% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Thursday, October 12th. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $16.00 price objective on shares of Opko Health in a research report on Monday, September 25th. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 23rd. Finally, J P Morgan Chase & Co cut shares of Opko Health from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $12.00 to $7.00 in a report on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $13.97.
A Lost Year For OPKO Health
Oct.12.17 | About: OPKO Health, (OPK)
OPKO Health has performed poorly in 2017 due to several minor setbacks.
The expectations cycle for the company was negative over the last 9-12 months but could soon change for the better.
The company has a stable commercial business, two approved pharmaceutical products, and a diverse pipeline.
There are several near-term catalysts that could lead to a share price turnaround.
2017 has been a tough year for OPKO Health (OPK). The stock is down more than 25% year to date, significantly underperforming the general market and its biotech peers. Looking at the chart, a bystander could have concluded that OPKO’s commercial business is imploding and that its pipeline is failing. This is certainly not the case – instead, OPKO is a victim of the expectations game. Rarely does a stock perform well when expectations are falling. And, while I believe OPKO is certainly worth much more than the current share price implies, the company has done little to make investors excited over the last 12 months:
Oct.12.17 | About: OPKO Health, (OPK)
OPKO Health has performed poorly in 2017 due to several minor setbacks.
The expectations cycle for the company was negative over the last 9-12 months but could soon change for the better.
The company has a stable commercial business, two approved pharmaceutical products, and a diverse pipeline.
There are several near-term catalysts that could lead to a share price turnaround.
2017 has been a tough year for OPKO Health (OPK). The stock is down more than 25% year to date, significantly underperforming the general market and its biotech peers. Looking at the chart, a bystander could have concluded that OPKO’s commercial business is imploding and that its pipeline is failing. This is certainly not the case – instead, OPKO is a victim of the expectations game. Rarely does a stock perform well when expectations are falling. And, while I believe OPKO is certainly worth much more than the current share price implies, the company has done little to make investors excited over the last 12 months:
- hGH-CTP failed in the phase 3 trial in adults. This is a minor setback for the company as the adult segment accounts for approximately 20% of the total market, but investors punished the stock, and this event marked the start of a decline from which the company is yet to recover.
- The diagnostics business is under pressure. More on this later.
- Rayaldee is having a slow launch. I warned about the possibility of a slow launch and expected it, but am still slightly disappointed with the results in the first six months of the launch.
- Partner Tesaro (NASDAQ:TSRO) received a CRL from the FDA for the IV version of its CINV drug Varubi.